Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score

Went, Philip; Agostinelli, Claudio; Gallamini, Andrea; Piccaluga, Pier Paolo; Ascani, Stefano; Sabattini, Elena; Bacci, Francesco; Falini, Brunangelo; Motta, Teresio; Paulli, Marco; Artusi, T; Piccioli, Milena; Zinzani, Pier Luigi; Pileri, Stefano

doi:10.1200/jco.2005.03.6327

Cited by 354 publications

(363 citation statements)

References 61 publications

(6 reference statements)

Supporting

Mentioning

338

Contrasting

Unclassified

Order By: Relevance

“…5) [9,[21][22][23][24]. Typically, the tumor cells of AITL have a T-helper cell phenotype expressing CD3, CD4, and frequently CD10, similar to a subset of normal GC-Th cells [23,25] (Table III).…”

Section: Angioimmunoblastic T-cell Lymphomamentioning

confidence: 99%

Intrafollicular neoplasia/“in situ” lymphoma: A proposal for morphology and immunodiagnostic classification

Carbone

Gloghini

2011

American J Hematol

View full text Add to dashboard Cite

Section: Angioimmunoblastic T-cell Lymphomamentioning

confidence: 99%

Intrafollicular neoplasia/“in situ” lymphoma: A proposal for morphology and immunodiagnostic classification

Carbone

Gloghini

2011

American J Hematol

View full text Add to dashboard Cite

“…In the 30 angioimmunoblastic T-cell lymphoma lymph node sections, laser-microdissection was performed: (i) for lymphoma cells, identified as CD3 þ CD10 þ medium-sized cells, [23][24][25] (ii) for CD34 þ endothelial cells, and (iii) for CD105 þ neoangiogenic endothelial cells, on different successive frozen sections.…”

Section: Laser-microdissection Combined To Molecular Analysesmentioning

confidence: 99%

BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma

et al. 2012

View full text Add to dashboard Cite

The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-cell lymphoma since its initial characterization. We have shown that angioimmunoblastic T-cell lymphoma endothelial cells produce vascular endothelial growth factor-A (VEGFA), and participate in lymphoma progression. In squamous cell carcinoma, endothelial BCL2 expression induces a crosstalk with tumor cells through VEGFA, a major mediator of tumoral angiogenesis. In the present study, we analyzed BCL2 and VEGFA in 30 angioimmunoblastic T-cell lymphomas, using triple immunofluorescence to identify protein coexpression in wellcharacterized lymphoma cells and microenvironment neoangiogenic endothelial cells. Using quantitative real-time PCR, we assessed mRNA expression levels in laser-microdissected endothelial and lymphoma cells. In lymphoma cells, as in endothelial cells, BCL2 and VEGFA proteins were coexpressed. BCL2 was expressed only in neoangiogenic CD34 þ CD105 þ endothelial cells. In laser-microdissected cells, mRNA studies showed a significant relationship between BCL2 and VEGFA levels in CD34 þ endothelial cells, but not in CD3 þ CD10 þ lymphoma cells, or in CD34 þ endothelial cells from lymph node hyperplasia. Further study showed that, in AITL, BCL2 mRNA levels in CD34 þ CD105 þ neoangiogenic endothelial cells also correlated with microvessel density, International Prognostic Index, Ann Arbor stage, bone marrow involvement and elevated LDH. BCL2 expression by CD105 þ neoangiogenic endothelial cells is related to tumor progression in angioimmunoblastic T-cell lymphoma.

show abstract

“…Went and colleagues proposed a new prognostic index based on the expression of 19 markers [Went et al 2006]. In this study, the proliferation-associated protein Ki-67 turned out to be prognostically relevant and was integrated in a new predictive score, incorporating age (>60 years), high lactate dehydrogenase, poor performance status, and Ki-67 80%.…”

Section: Molecular and Immunohistochemical Prognostic Factorsmentioning

confidence: 99%

Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond

Foss

2011

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Abstract:The peripheral T-cell lymphomas are a rare, heterogeneous group of non-Hodgkin's lymphomas which have an aggressive clinical course. Treatment approaches have traditionally been similar to those of diffuse large B-cell lymphomas, but outcomes have been inferior. Novel approaches involving agents and pathways developed from a better understanding of the biology of the diseases have led to therapeutic advances. The introduction of new agents, including antifolates, immunoconjugates, histone deacetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling inhibitors have improved outcomes for patients with relapsed and refractory disease and are being incorporated into strategies for first-line therapy. Stem cell transplantation remains a potentially curative option for a subset of patients.

show abstract

Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score

Cited by 354 publications

References 61 publications

Intrafollicular neoplasia/“in situ” lymphoma: A proposal for morphology and immunodiagnostic classification

Intrafollicular neoplasia/“in situ” lymphoma: A proposal for morphology and immunodiagnostic classification

BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma

Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond

Contact Info

Product

Resources

About